Terveystalo Oyj

Terveystalo Plc announced that Petri Bono, Chief Medical Officer and Executive Team member since 2019, will leave the company on 14 August 2024 for a new position outside the company. Ville Iho, President and CEO, praised Bono's leadership during his tenure, particularly during the coronavirus pandemic, and highlighted the company's shift towards customer-oriented development and integrated treatment paths. Bono expressed pride in the advancements made in medical quality and healthcare modernization at Terveystalo. The responsibilities of the Chief Medical Officer will be temporarily distributed among the company's medical management. Terveystalo Plc is the largest private healthcare service provider in Finland and a leading occupational health provider in the Nordic region, with extensive digital and clinic-based services.

Terveystalo's Half-Year Report for 2024 highlights a strong second quarter with record revenue and profitability. Revenue increased by 6% to EUR 340 million, and adjusted EBITA rose by nearly 50% to EUR 43 million. Earnings per share grew by 91% to EUR 0.11. The Healthcare Services segment saw an 11% increase in revenue to EUR 261 million, boosting the adjusted EBITA by 67%. The Portfolio businesses segment's adjusted EBITA also improved by 52% despite a 9% revenue decline. In Sweden, revenue decreased by 10% to EUR 22 million due to expired contracts and weakened demand. Terveystalo has raised its 2024 guidance, expecting full-year revenue growth and an adjusted EBITA margin of 11.5–12.5%. The profit improvement program has exceeded expectations, significantly enhancing profitability. The company plans a webcast and conference call on 17 July 2024 to discuss the results.

Terveystalo Plc announced on 11 July 2024 that its profit improvement program has progressed faster than expected, leading to an upward revision of its profitability guidance for 2024, while revenue guidance remains unchanged. President and CEO Ville Iho credited the company's employees for their role in achieving these results. The new guidance expects full-year 2024 revenue to grow from EUR 1,286 million in 2023, with adjusted EBITA projected to be 11.5–12.5% of revenue, up from the previous guidance of 10.5–11.5%. Preliminary data for Q2 2024 shows revenue of approximately EUR 340 million and adjusted EBITA of around EUR 42 million, or 12.5% of revenue. The estimates consider inflation, consumer demand, employment, and normal morbidity but exclude significant acquisitions or divestments. The Sweden segment's revenue is expected to decline due to macroeconomic factors, and the VAT increase in Finland is not expected to significantly impact results. Terveystalo will release its half-year financial report on 17 July 2024.

Terveystalo Plc reported a managers' transaction involving Rettig Investment AB, which is closely associated with Matts Rosenberg, a member of Terveystalo's Board. The transaction, dated June 27, 2024, involved the acquisition of 21,153,191 shares at a unit price of 0 EUR. This internal restructuring resulted from the merger of Rettig Group AB into Rettig Investment AB, transferring the shares to Rettig Investment AB. The notification was distributed to Nasdaq Helsinki Oy and principal media.

On 28 June 2024, Terveystalo Plc announced that Rettig Investment AB's ownership in Terveystalo has increased to 16.65%, comprising 21,153,191 shares out of a total of 127,036,531 shares. This change occurred due to an internal restructuring where Rettig Group AB merged into Rettig Investment AB on 27 June 2024, transferring the shares accordingly. Terveystalo is the largest private healthcare provider in Finland and a leading occupational health provider in the Nordic region, with extensive digital and physical services. The company is listed on the Helsinki Stock Exchange and employs over 15,500 professionals.